EN DE
STOCK COMPARISON

Camurus AB vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Camurus AB (CAMX) and Vertex Pharmaceuticals (VRTX) compare, as of Sep 5, 2026.

As of Sep 5, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Camurus AB trades at SEK 587 versus a fair value of SEK 269 (-54%), while Vertex Pharmaceuticals trades at $558 versus $279 (-50%).
Camurus AB
CAMX.ST · SEK · Health Care
-54%
upside to fair value
overvalued
PriceSEK 587
Fair ValueSEK 269
Quality72/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-50%
upside to fair value
overvalued
Price$558
Fair Value$279
Quality79/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Camurus ABVertex Pharmaceuticals
Valuation
52.3×P/E (TTM)28.8×
14.87×P/S (TTM)10.06×
7.87×P/B6.59×
36.0×EV/EBITDA23.8×
—PEG1.72×
−54.1%Fair value upside−50.0%
—Dividend yield0.1%
Profitability
32%Operating margin38%
—EBIT margin trend (5Y)0.86×
17%Return on equity24%
11%Return on assets12%
Growth
-5%Revenue growth (YoY)8%
33.3%Avg. growth/yr (3Y)10.6%
46.5%Avg. growth/yr (5Y)14.2%
+42.3%Value creation/yr+13.6%
Balance & size
153.6×Interest coverage (EBIT/interest)357.9×
—Debt / equity0.03×
$3BMarket cap$123B
healthyGrowth qualityhealthy

Vertex Pharmaceuticals leads: 3 to 8 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Camurus ABof which business quality 74 · market factors 47 Vertex Pharmaceuticalsof which business quality 77 · market factors 79
ProfitabilityMargins and returns on capital today
73
72
Quality GrowthAre margins and returns improving?
74
65
CashflowEarnings quality: real cash, not paper profit
82
79
Fin. StrengthBalance sheet, leverage, solvency risk
100
92
InvestmentDisciplined investing over empire-building
26
58
Low VolatilityCalm price path (market factor)
61
85
MomentumPrice trend over the last 3–12 months (market factor)
47
70
52W MomentumDistance to the 52-week high (market factor)
30
89
Net IssuanceBuybacks instead of dilution
63
82

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyCamurus ABPrice SEK 587Vertex PharmaceuticalsPrice $558
DCF Models-30%below the priceSEK 408-19%below the price$453
Earnings-Based-27%below the priceSEK 429-8%close to the price$516
Dividend Discountn/a-99%below the price$7.07
Multiples-59%below the priceSEK 239-50%below the price$278
Asset-Based-92%below the priceSEK 47.23-91%below the price$49.27
Growth DCF-38%below the priceSEK 365-38%below the price$348
Economic Profit-72%below the priceSEK 164-54%below the price$254
Growth Earnings-3%close to the priceSEK 569+24%above the price$692
Minimum-92%below the priceSEK 47.23-99%below the price$7.07
Maximum-3%close to the priceSEK 569+24%above the price$692
Median-38%below the priceSEK 365-44%below the price$313
Geometric mean-57%below the priceSEK 254-67%below the price$185

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Camurus AB: 24 of 24 models see the stock below the current price.

Vertex Pharmaceuticals: 22 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Camurus AB
Bear SEK 202Fair Value SEK 269Bull SEK 325
SEK 587 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$558 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Camurus AB · Health Care

Quality score72 · Top 25%
Fair value upside-54% · below median

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-50% · below median

Bottom line

As of Sep 5, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Camurus AB trades at SEK 587 versus a fair value of SEK 269 (-54%), while Vertex Pharmaceuticals trades at $558 versus $279 (-50%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →
Camurus AB · Vertex Pharmaceuticals

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Camurus AB

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupMerck & Company vs UnitedHealth Group

Related to Vertex Pharmaceuticals

AstraZeneca vs UnitedHealth GroupThermo Fisher Scientific vs UnitedHealth GroupAmgen vs UnitedHealth GroupAbbott Laboratories vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.